RFG Advisory LLC Acquires 748 Shares of Danaher Co. (NYSE:DHR)

RFG Advisory LLC increased its holdings in Danaher Co. (NYSE:DHR) by 11.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 7,303 shares of the conglomerate’s stock after buying an additional 748 shares during the period. RFG Advisory LLC’s holdings in Danaher were worth $1,825,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the company. Dnca Finance purchased a new position in Danaher in the second quarter valued at approximately $14,966,000. Parisi Gray Wealth Management lifted its stake in Danaher by 1.8% in the second quarter. Parisi Gray Wealth Management now owns 15,602 shares of the conglomerate’s stock valued at $3,898,000 after purchasing an additional 278 shares during the last quarter. Coastline Trust Co lifted its stake in Danaher by 2.0% in the second quarter. Coastline Trust Co now owns 11,461 shares of the conglomerate’s stock valued at $2,864,000 after purchasing an additional 224 shares during the last quarter. Czech National Bank lifted its stake in Danaher by 8.6% in the second quarter. Czech National Bank now owns 125,619 shares of the conglomerate’s stock valued at $31,386,000 after purchasing an additional 9,906 shares during the last quarter. Finally, Mirador Capital Partners LP lifted its stake in Danaher by 2.7% in the second quarter. Mirador Capital Partners LP now owns 22,864 shares of the conglomerate’s stock valued at $5,713,000 after purchasing an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR traded down $0.99 during trading on Monday, reaching $267.12. The stock had a trading volume of 1,311,297 shares, compared to its average volume of 2,888,990. The stock has a market cap of $197.85 billion, a PE ratio of 45.44, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business has a 50-day moving average of $257.31 and a 200-day moving average of $252.45.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $2.05 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insider Activity

In other news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,797 shares of company stock valued at $18,039,944. 11.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on DHR shares. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Barclays increased their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group increased their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Stifel Nicolaus increased their target price on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada increased their price objective on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.